Ignite Creation Date:
2025-12-25 @ 12:04 AM
Ignite Modification Date:
2025-12-25 @ 10:03 PM
Study NCT ID:
NCT04895358
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-03-03
First Post:
2021-05-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-06-18
Start Date Type:
ACTUAL
Primary Completion Date:
2027-12-18
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12-18
Completion Date Type:
ESTIMATED
First Submit Date:
2021-05-17
First Submit QC Date:
None
Study First Post Date:
2021-05-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-02-27
Last Update Post Date:
2025-03-03
Last Update Post Date Type:
ACTUAL